clinical trial · NCT07617337
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
ALK Positive Non-small Cell Lung CancerAQUA07Lorlatinib
brief summary
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.
started
Jul 31, 2026
primary completion
Aug 31, 2030
completion
Aug 31, 2030
last updated
Jun 1, 2026
official title
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of AQUA07 Monotherapy and Combination Therapy in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol